ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0869

PD-1 inhibitor unleashes pathogenic CD8+ T cells and induce arthritis in collagen-primed mice

Clement Adedeji1, Muhammad Hamdan1, Hong-Jai Park2, Kelsey Wang1 and Sang Kim3, 1Yale University, New Haven, 2Yale University, New Haven, CT, 3Yale University, Branford, CT

Meeting: ACR Convergence 2025

Keywords: Collagen, Inflammation, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Rheumatoid Arthritis – Animal Models (0867–0872)

Session Type: Abstract Session

Session Time: 10:30AM-10:45AM

Background/Purpose: Background/Purpose: Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events, including inflammatory arthritis (ICI-arthritis). The pathophysiology of ICI-arthritis, particularly the role of T cells, remains unclear due to the lack of preclinical murine models.

Methods: We immunized 8-12-week-old C57BL/6 mice with type II chicken collagen (CII) Two to three weeks later, we administered a PD-1 inhibitor and measured arthritis scores until the mice were euthanized. Inflamed joints (knees) and CII-draining lymph nodes (dLNs) were harvested for immunologic and histological analyses.

Methods: We immunized 8-12-week-old C57BL/6 mice with type II chicken collagen (CII) Two to three weeks later, we administered a PD-1 inhibitor and measured arthritis scores until the mice were euthanized. Inflamed joints (knees) and CII-draining lymph nodes (dLNs) were harvested for immunologic and histological analyses.

Results: Mice primed with CII but without PD-1 inhibitors (CII_No PD-1i) or mice that did not receive CII but were given PD-1 inhibitors (No CII_PD-1i) did not develop arthritis. In contrast, CII-primed mice began developing arthritis 4-5 days after the initiation of PD-1 inhibitors, recapitulating human PD-1i-induced arthritis. The severity of arthritis at euthanasia was comparable between mice with PD-1i arthritis and conventional collagen-induced arthritis (CIA) mice. Histological analysis of the knee joints showed inflammation and joint destruction in CII_PD-1i mice. The numbers of CD45+ immune cells were increased in the joint and draining lymph nodes (dLN) in CII_PD-1i mice compared to the CII_No PD-1i and No CII_PD-1i groups. Notably, CD8+ T cells were expanded in the inflamed joints and dLNs of CII_PD-1i mice. Furthermore, these CD8+ T cells produced inflammatory cytokines including IFNγ and TNFα in response to CII. Levels of pathogenic CII-specific antibodies in CII_PD-1i mice were lower than in CIA, suggesting that the pathogenesis of PD-1i arthritis differs from that of rheumatoid arthritis.

Conclusion: CII-primed mice developed de novo arthritis following PD-1 inhibition, suggesting that these mice can serve as a murine model of PD-1i arthritis. Of note IFNg+ TNFa+ CD8+ T cells are expanded in these mice, indicating that PD-1 inhibitor unleashes pathogenic CD8+ T cells in CII-primed mice.


Disclosures: C. Adedeji: None; M. Hamdan: None; H. Park: None; K. Wang: None; S. Kim: None.

To cite this abstract in AMA style:

Adedeji C, Hamdan M, Park H, Wang K, Kim S. PD-1 inhibitor unleashes pathogenic CD8+ T cells and induce arthritis in collagen-primed mice [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/pd-1-inhibitor-unleashes-pathogenic-cd8-t-cells-and-induce-arthritis-in-collagen-primed-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pd-1-inhibitor-unleashes-pathogenic-cd8-t-cells-and-induce-arthritis-in-collagen-primed-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology